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Abstract: Hepatocellular carcinoma (HCC) is the fifth most common neoplasm and the third 
leading cause of cancer-related deaths worldwide. Cirrhosis, most often due to viral hepatitis, 
is the predominant risk factors for HCC and geographical differences in both risk factors and 
incidence are largely due to epidemiological variations in hepatitis B and C infection. Hepatic 
function  is  a  relevant  parameter  in  selecting  therapy  in  HCC.  The  current  clinical 
classification of HCC split patients into 5 stages, with a specific treatment schedule for any 
stage. As patients with early stages can receive curative treatments, such as surgical resection, 
liver  transplantation  or  local  ablation,  surveillance  program  in  h
become mandatory. Sorafenib, a multikinase inhibitor, has recently shown survival benefits in 
patients at advanced stage of disease. Hopefully, new molecular targeted therapies and their 
combination  with  sorafenib  or  interventional
therapeutic armamentarium against HCC.
Introduction:  Hepatocellular carcinoma  (HCC) 
currently  ranks  fifth  in  global  cancer  incidence 
representing  the  third  cause  of  cancer
death
1. 
In  70-90%  of  cases  HCC  develops  on  the 
background  of  cirrhosis  or  chronic  liver 
inflammation  (hepatitis)  and  it  is  currently  the 
leading cause of death among cirrhotic patients
Risk  factors  and  etiologies  vary  among 
geographical  regions:  chronic  hepatitis  C  viral 
infection  (HCV)  represents  the  predominant  risk 
factors  in  western  countries  and  Japan,  while 
chronic  hepatitis  B  viral  infection  (HBV)  is  the 
main  predisposing  factor  in  Asia  and  Africa. 
Hepatitis  B  carriers are  100  times  more  likely  to 
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Hepatocellular carcinoma (HCC) is the fifth most common neoplasm and the third 
related deaths worldwide. Cirrhosis, most often due to viral hepatitis, 
isk factors for HCC and geographical differences in both risk factors and 
incidence are largely due to epidemiological variations in hepatitis B and C infection. Hepatic 
function  is  a  relevant  parameter  in  selecting  therapy  in  HCC.  The  current  clinical 
ssification of HCC split patients into 5 stages, with a specific treatment schedule for any 
stage. As patients with early stages can receive curative treatments, such as surgical resection, 
liver  transplantation  or  local  ablation,  surveillance  program  in  high-risk  populations  has 
become mandatory. Sorafenib, a multikinase inhibitor, has recently shown survival benefits in 
patients at advanced stage of disease. Hopefully, new molecular targeted therapies and their 
combination  with  sorafenib  or  interventional and  surgical  procedures,  should  expand  the 
therapeutic armamentarium against HCC.
carcinoma  (HCC) 
currently  ranks  fifth  in  global  cancer  incidence 
representing  the  third  cause  of  cancer-related 
90%  of  cases  HCC  develops  on  the 
background  of  cirrhosis  or  chronic  liver 
inflammation  (hepatitis)  and  it  is  currently  the 
ng cause of death among cirrhotic patients
2.
Risk  factors  and  etiologies  vary  among 
geographical  regions:  chronic  hepatitis  C  viral 
infection  (HCV)  represents  the  predominant  risk 
factors  in  western  countries  and  Japan,  while 
chronic  hepatitis  B  viral  infection  (HBV)  is  the 
n  Asia  and  Africa. 
Hepatitis  B  carriers are  100  times  more  likely  to 
develop HCC than the uninfected persons with an 
annual incidence of 0.5% in non
of 2-6% in cirrhotic patients 
established HCV-related cirrhosi
HCC is between 2%-8% per year
New in the epidemiology of HCC, especially in 
the  west,  is  the  emerging  role  of  the  metabolic 
syndrome, related to obesity and insulin resistance, 
as  an  important  risk  factor  along  with  the 
established role of high consumption of alcohol
Differently  from  other  neoplasms,  HCC 
behaviour  is  rather  peculiar  with  prognosis 
determined not only by the tumoral disease but also 
by the severity of the underlying liver disease. 
few  years  ago,  HCC  was  a  malignancy  typically 
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related deaths worldwide. Cirrhosis, most often due to viral hepatitis, 
isk factors for HCC and geographical differences in both risk factors and 
incidence are largely due to epidemiological variations in hepatitis B and C infection. Hepatic 
function  is  a  relevant  parameter  in  selecting  therapy  in  HCC.  The  current  clinical 
ssification of HCC split patients into 5 stages, with a specific treatment schedule for any 
stage. As patients with early stages can receive curative treatments, such as surgical resection, 
risk  populations  has 
become mandatory. Sorafenib, a multikinase inhibitor, has recently shown survival benefits in 
patients at advanced stage of disease. Hopefully, new molecular targeted therapies and their 
and  surgical  procedures,  should  expand  the 
develop HCC than the uninfected persons with an 
annual incidence of 0.5% in non-cirrhotic cases and 
6% in cirrhotic patients 
3,4 In patients who have 
related cirrhosis the incidence of 
8% per year
5.
New in the epidemiology of HCC, especially in 
the  west,  is  the  emerging  role  of  the  metabolic 
syndrome, related to obesity and insulin resistance, 
as  an  important  risk  factor  along  with  the  well-
established role of high consumption of alcohol
6.
Differently  from  other  neoplasms,  HCC 
behaviour  is  rather  peculiar  with  prognosis 
determined not only by the tumoral disease but also 
by the severity of the underlying liver disease. Until 
o,  HCC  was  a  malignancy  typically Medit J Hemat Infect Dis 2009; 1(3); Open Journal System 
diagnosed at an advanced stage with  a very poor 
prognosis. Nowadays, a wider range of therapeutic 
options can be offered including surgical resection,
orthotopic  liver  transplantation  (OLT), 
percutaneous  ablation  procedures,  intra-arterial 
treatments  and,  more  recently,  molecular  targeted 
therapies 
7.
In  addition,  since  it  has  well  established  that 
treatment is more effective when HCC is diagnosed 
at  an  early  stage,  efforts  to  improve  diagnostic 
process  and  surveillance  policy  have  assumed  a 
major  role  in  the  management  of  HCC
8.  In  this 
article  we  report  a  summary  of  the  most  recent 
information on novel advancements in the treatment 
of this neoplasm.
Surveillance  and  Diagnosis:  The  aim  of  HCC 
surveillance is to reduce mortality from the disease. 
A  randomized  controlled  trial  showed  that  HCC 
surveillance with liver ultrasound and serum alfa-
fetoprotein  (AFP)  every  6  months  improved 
survival  in  Chinese  patients  infected  with  HBV 
irrespective  of  the  presence  of  cirrhosis
9.  Results 
from  two  european  cohort  studies  confirm  the 
potential  benefits  of  this  policy,  especially  in 
countries with high prevalence of disease
10,11.
Surveillance  for  HCC  should  be  performed 
using  ultrasonography. Ultrasound  has  been 
reported to have a sensitivity of between 65% and 
80% with a specificity greater than 90% when used 
as a screening test; this performance, at present, is 
superior  to  that  of  any  of  the  available  serologic 
tests
10. 
With regard to AFP, a value of 20 ng/mL has 
shown  a  good  balance  between  sensitivity  and 
specificity. However, at this level the sensitivity is 
only 60%, and therefore AFP alone should not be 
used for sceening
12. 
Proteomic research represents now a promising 
way but at present valid tumor markers have still 
not reached the clinical setting.
Surveillance with ultrasound every 6 months for 
detection of early HCC is recommended in cirrhotic 
patients and other specific risk groups
5 (Table 1).
According to published guidelines, a diagnosis 
of HCC can be made in patients with cirrhosis who 
have  a  nodule  greater  than  2  cm  identified  on  a 
dynamic  imaging  technique  (CT  scan,  contrast 
ultrasound  or  MRI  with  contrast)  with  a  typical 
vascular  pattern  (i.e.,  hyper-enhancement  in  the 
arterial  phase  with  wash-out  in  the  portal/venous 
phase)
5,13. In patients with nodule greater than 2 cm 
but  an  atypical  vascular  pattern  on  imaging,  a 
biopsy is recommended. Nodules between 1 and 2 
cm  presenting  characteristic  arterial  enhancement 
features  with  venous  wash-out  on  2  different 
imaging modalities should be considered as HCC. 
Whether the typical vascular pattern is detected on a 
single  imaging  technique,  a  biopsy  should  be 
performed. 
Nodules found on ultrasound surveillance that 
are  smaller  than  1  cm  should  be  followed  with 
ultrasound every  3  to  4  months  to  detect  growth 
suggestive of malignant evolution.
If the hepatic lesion remains stable after 2 years, 
the patient can return to the standard surveillance of 
every 6 to 12 months.
In clinical practice the characterization of small 
hepatic  nodules  by  imaging  techniques  remains 
difficult  in  a  not  negligible  percentage  of  cases. 
Results from a previous study of this group have 
show  that  non-invasive  criteria  for  diagnosis  of 
HCC are  satisfied in  only 60% of small nodules. 
Moreover,  it  should  be  also  considered  that  truly 
hypovascular HCC do exist, particularly in nodules 
of 1 to 2 cm where they reach the figure of 17% 
14.
Staging: An accurate staging of the tumor before 
considering  treatment  of  HCC  is  mandatory  to 
estimate prognosis and decide which therapy may 
offer the greatest survival potential. 
The  so-called  Barcelona-Clinic  Liver  Cancer 
(BCLC) is the most widely accepted staging system 
(Figure  1).  It  includes  different  variables  (tumor 
stage, liver function, physical status, cancer related 
symptoms)  and  links  staging  with  treatment 
modalities and with an estimation of life expectancy 
that  is  based  on  published  response  rates  to  the 
various treatments
15. 
This system stratifies patients into 5 stages that 
identify  the  ideal  candidates  for  the  therapies 
currently available. Patients with a single lesion less 
than 2 cm, who are asymptomatic and do not show 
vascular  invasion  or  satellites  represent  the  so-
called  “very  early”  HCC.  This  is  a  very  well-
differentiated  HCC  which  correlates,  from  the 
pathological  perspective,  with  the  carcinoma  “in 
situ” stage. The absence of microvascular invasion 
and dissemination  offers the highest likelihood of 
cure. Results from Japanese studies have shown in 
these  patients  excellent  outcome  in  terms  of 
survival. Ninety percent and 71% after 5 years can 
be  achieved  with  surgical  resection  or 
radiofrequency ablation (RFA), respectively with a 
recurrence rate of 8% at 3 years
16,17 . “Early-stage” 
disease is characterized by preserved liver function 
(Child-Pugh  class  A  or  B),  and  refers  to  HCC 
whitin the Milan criteria: single HCC of 5 cm orMedit J Hemat Infect Dis 2009; 1(3); Open Journal System 
Table 1.  Patients at risk for developing HCC who should be entered into surveillance programme (modified from Bruix J and 
Sherman M 
77).
 Cirrhosis regardless of the aetiology
 High risk groups of hepatitis B carriers: asian males  40 years, asian females  50 years, family history of HCC, africans > 
20 years, chronic B hepatitis with high HBV DNA levels and those with high degree of hepatic inflammatory activity.
 Hepatitis C
 Genetic hemochromatosis
Patients  with alpha1-antitrypsin  deficiency, non-alcoholic steatohepatitis,  autoimmune  hepatitis  have  an  increased  risk of HCC. 
However, because of paucity of data, no recommendations for or against surveillance can be made.
less, or up to 3 lesions less than 3 cm each, without 
vascular infiltration neither lymph node or distant 
metastases
18.    These  patients  can  be  effectively 
treated by therapies having curative intents such as 
surgical  resection,  liver  transplantation  (OLT)  or 
local ablation, with a reported 5-year survival rates 
of 50–75%
18,19,20. 
The  choice  of  therapy  is  not  univocal  and  it 
should be based on severity of the liver dysfunction, 
presence  of  portal  hypertension,  medical 
comorbidities.
Patients  with  compensated  cirrhosis  and 
without  HCC-related  symptoms  or  vascular 
invasion  that  are  outside  of  the  criteria  of  “very 
early”  or  “early”  stage correspond  to  the 
“intermediate” stage HCC. Untreated patients at this 
stage  present  a  median  survival  of  16  months. 
Transarterial chemoembolization (TACE) raises the 
median survival of these patients to 19-20 months 
and is now regarded the standard care at this stage
21.
Patients who have symptomatic tumors and/or 
invasive  tumoral  pattern  (vascular 
invasion/extrahepatic  spread)  identify  the 
“advanced” stage. 
Until two years ago, lack of treatment options 
for patients at advanced stage produced a median 
survival  of  6  months.  Sorafenib,  a  multityrosine 
kinase inhibitor, has recently become the standard 
of care for these patients as it is the only treatment 
proven to prolong the survival in this setting
22 .
Patients  with  extensive  tumor  involvement 
leading  to  severe  cancer-related  symptoms  and/or 
major impairment of liver function (Child–Pugh C) 
are considered as “end stage”. These patients have a 
life expectancy less than 3-6 months. They are not 
likely  to  benefit  with  any  of  the  treatments 
aforementioned  and  should  be  treated  only  with 
symptomatic therapy.
Treatment: Treatment of HCC is multidisciplinary 
and  involves  hepatologists,  oncologists,  surgeons, 
and interventional radiologists. Several factors such 
as  severity  of  underlying  liver  disease,  tumor 
burden, physical status, associated diseases as well 
as availability and expertise in surgical and ablative 
therapies,  should  be  considered  before  deciding 
therapeutic strategy.
Treatments for HCC have been conventionally 
divided into curative and palliative.
Curative treatments such as surgical resection, 
liver  transplantation  and  percutaneous  ablation, 
achieve complete responses in a high proportion of 
patients  and  are  expected  to  improve  survival. 
Palliative treatments are not aimed to cure but can 
obtain  good  response  rates  and  also  prolong 
survival in some cases.
Despite  a  wide  diffusion  of  surveillance 
strategy among cirrhotic patients, only 30–40% of 
patients in western countries can undergo curative 
treatments
23.
Resection is the treatment of choice for HCC in 
non-cirrhotic  patients  who  represent  however  just 
5% of cases in the west
24.
In the absence of cirrhosis, surgical resection of 
this tumour is less likely to produce liver failure. 
Patients  with  HCC  and  concomitant  cirrhosis  are 
not all suitable for resection because of the risk for 
hepatic  decompensation  after  surgical  resection. 
Strict  selection  criteria  are  therefore  required  to 
avoid hepatic decompensation. 
Nowadays this procedure is recommended only 
in patients with a single HCC and a well preserved 
liver  function  (Child  Pugh  A),  with  a  normal 
bilirubin  level  and  in  the  absence  of  portal 
hypertension  (defined  as  the  presence  of 
oesophageal  varices,  platelet  count  of  less  than 
100.000/µl  or  splenomegaly).  Due  to  progress  in 
surgical treatment, in these subjects survival rates at 
5  years  exceedes  70  %  while  treatment  related 
mortality is less than 3%
25. 
Tumor recurrence complicates 50% of cases at 
3 years and 70% at 5 years after resection and are 
due  to  either  growth  of  intrahepatic  metastases 
understaged at pre-operative imaging studies or to 
the development of “de novo” tumors
20,26,27,28.
Recurrence due to understaged HCC are usually 
observed  within  the  first  two  years  of  follow-up, 
while metachronic tumours develop later. Medit J Hemat Infect Dis 2009; 1(3); Open Journal System 
Figure 1. Barcelona Clinic Liver Cancer (BCLC) staging classification (modified from Bruix J and Sherman M
77 ) 
Non-anatomical  resection,  presence  of 
microscopic  vascular  invasion  and  histological 
differentiation,  are  well-known  predictor  of 
recurrence and survival
29. 
Thus,  differently  from  percutaneous  ablation, 
surgical  resection  can  provides  relevant 
informations about risk of recurrence and allows a 
risk-based enlistment for OLT. 
Gene  signature  identification  in  liver  tissue 
adjacent to the tumor, has been recently reported as 
promising tool to identify the patients at highest risk 
for  recurrence  of  HCC,  with  the  aim  to  adopt 
intensive  clinical  follow-up  or  chemopreventive 
strategies in such patients
30 .
The  substantial  recurrence  rate  has  led  to 
explore  the  potential  benefit  of  adjuvant  therapy, 
including systemic or hepatic-artery chemotherapy 
or chemoembolization, after resection. At present, 
however,  definitive  data  and  firm  conclusions  in 
this setting are still lacking
31.
It  has  been  shown  that  partial  hepatectomy, 
when  patients met the Milan criteria, allows a  5-
year  survival  rate  of  78.2%,  as  in  the  case  of 
patients  underwent  OLT,  a  procedure  which  is 
instead  dependent  on  availability  of  organs. 
Therefore, partial hepatectomy should be regarded 
as  the  appropriate  strategy  to  treat  well  selected 
patients
32.
Liver  transplantation, in  theory, would  be the 
optimal  therapeutic  option  for  HCC  as  it 
simultaneously removes the tumor and underlying 
cirrhosis  thus  minimizing  the  risk  of  HCC 
recurrence.  The  best  candidates  for  liver 
transplantation  are  those  satisfying  the  Milan 
criteria.  In these  patients the  survival rate after  5 
years exceeded 70%, with a recurrence of less than 
15%
18,19 . Organ allocation policy is based on the 
Model for End-Stage Liver Disease (MELD) score 
with the aim to transplant patients with the highest 
short-term  risk  of  mortality. At  present,  the  great 
limit of this therapeutic option is the organ shortage 
which increases waiting time and leads about 20% 
of  patients  to  drop  out  before  receiving  the 
transplantation
19,33.  No  definitive  therapeutic 
strategies  have been  validated  at  present to  delay 
tumor  progression  while  listing.  TACE,  however, 
seem  to  reduce  tumor  burden  and  to  delay 
progression even if it can precipitate liver failure
34 . 
Percutaneous  ablation  is  cost-effective  when Medit J Hemat Infect Dis 2009; 1(3); Open Journal System 
waiting time is longer than 6 months but the risk of 
tumor seeding should not be disregarded
35
The  major  questions currently related to  liver 
transplantation for HCC are whether Milan criteria 
can be safely expanded, how to increase the scarce 
supply  of  donor  organs,  to  assess  the  benefit  of 
adjuvant  therapies,  such  as  percutaneous  ablation 
and chemoembolization or systemic therapy, whilst 
patients are on the waiting list
36-45.
Non-surgical  treatment  of  hepatocellular 
carcinoma
Patients  who  are  not  candidates  for  surgical 
treatments,  due  to  either  tumor  characteristics  or 
underlying  liver  disease,  can  be  considered  for 
locoregional  therapies,  such  as  ablation, 
chemoembolization and radioembolization, or new 
therapies.
Percutaneous  ablation:  Because  of  several 
contraindications and the mortality and morbidity of 
surgery,  alternative  treatments  have  been 
developed.  Percutaneous  ablation  include  several 
minimally  invasive  techiniques  consisting  in  the 
injection of chemicals (absolute ethanol, acetic acid, 
boiling  saline)  in  the  HCC  nodule  or  its  thermal 
destruction  (radiofrequency,  microwave, laser  and 
cryoablation)
46.
Generally  it  has  performed  under  ultrasound 
guidance but it can be also done under CT or MRI 
control or during laparotomy or laparoscopy. These 
techiniques  are  inexpensive,  require  short 
hospitalization  time  and  present  rare 
complications
47.  Major  contraindications  are 
presence  of  ascites,  severe  hemostasis  disorders 
(platelet count less than 50.000/mm
3, prothrombin 
activity  less  than  50%),  severe  liver  impairment, 
neoplastic vein thrombosis. 
48  Treatment efficacy, 
defined as absence of contrast uptake on a dynamic 
imaging technique (CT scan, contrast ultrasound or 
MRI  with  contrast),  can  be  evaluated  one  month 
after the procedure.
Percuteneous  ablation,  usually  by 
radiofrequency  ablation  (RFA)  and  percutaneous 
ethanol  injection  (PEI),  is  the  best  therapeutic 
option in patients with early, unresectable HCC.
49,50
PEI, the first percutaneous technique introduced 
in clinical practice, is widely available and a well-
tolerated  procedure  with  few  side  effects,  but 
requires repeated injections on separated days. The 
rate of complete necrosis is closely correlated with 
tumor  size;  PEI  has  been  reported  to  induce 
chemical  coagulative  necrosis  in  70%  to  80%  of 
solitary HCC sized 3 cm or less and in almost 100% 
in  tumors  less  than  2  cm;  however,  its  efficacy 
drops to 50% in lesions between 3 and 5 cm likely 
because of the presence of septa inside the lesion 
that limit the spread of ethanol 
46,48.
RFA  achieves  thermal  coagulation  using  an 
alternating  electric  current.  It  produce  a  similar 
level of response as PEI in tumors less than 2 cm 
but with fewer sessions and may determine better 
results in tumors greater than 2 cm.
49 .  According 
to guidilines of American Association for the Study 
of Liver Diseases (AASLD), RFA is the first option 
to be considered in tumors greater than 2 cm
51,52.  
Moreover,  a  recent  meta-analysis  of  randomized 
controlled  trials  comparing  PEI  with  RFA  has 
demonstrated  that  RFA  offers  a  better  3-year 
survival  than  PEI  (63%  to  81%  in  RFA-treated 
patients  versus  48%  to  67%  in  PEI-treated 
patients)
52 .
The main limit of RFA is the rate of adverse 
events  which  is  higher  than  that  with  ethanol. 
Mortality rates ranging from 0.1 to 0.3% and severe 
complication  rate  up  to  10% 
53-55.  Major 
complications  included  peritoneal  bleeding, 
pneumothorax, intestinal perforation, liver abscess, 
pleural effusion and bile duct stenosis
56. 
Specific  contraindication  for  the  use  of  RFA 
include: poorly differentiated tumors or subcapsular 
location due to a higher seeding risk, location of the 
tumor  adjacent  to  the  gastrointestinal  tract,  large 
bile ducts and large blood vessels
53.
Recent  studies  have  tried  to  compare  PEI  or 
RFA with surgical resection in paients with early 
HCC candidates to surgery. Although no definitive 
answer can be drawn, percutaneous ablation seem 
to achieve similar survival and disease-free survival 
than surgical resection, but with lower morbidity
57-
60.  Similar  to  surgical  resection,  percutaneous 
ablation  shows  high  rates  of  recurrence  during 
follow-up that may reach 70% at 5 years
48.
Transarterial  Chemoembolization:  Transarterial 
chemoembolization  (TACE)  is  considered  as  the 
first  line  non-curative  therapy  for  non-surgical 
patients with large/multifocal HCC who do not have 
vascular  invasion  or  extrahepatic  spread  (BCLC 
intermediate stage). The rationale of this procedure 
is based on the knowledge of tumor vascularization: 
tumors > 2 cm mainly receive their blood supply 
from  the  end  branches  of  hepatic  artery  and  not 
from  portal  vein
61.  The  complete  procedure 
associates  injection  in  the  hepatic  artery  of  a 
cytotoxic drug mixed with lipiodol (ethiodized oil), 
an  oily  contrast  agent,  followed  by  embolization 
usually by means of absorbable gelatin (Gelfoam) 
particles. Medit J Hemat Infect Dis 2009; 1(3); Open Journal System 
Cytotoxic drugs are preferentially delivered in 
the  tumor  and,  when  mixed  with  lipiodol,  are 
progressively delivered inside the tumor. The most 
frequently  used  cytotoxic  drugs  are  cisplatin  and 
doxorubicin, which are amphiphilic and likely more 
retained in lipiodol, allowing an increased contact 
with tumoral tissue. Lipiodol remains embolized in 
the tumoral vessels and contributes, in addition to 
the  embolizing  agent,  to  ischemic necrosis of the 
tumor
48.
The  procedure  should  be  as  selective  as 
possible  to  target  just  the  tumor  and  to  avoid 
ishemic  damages  to  the  surrounding  liver 
parenchima.
Contraindications for TACE include absence of 
effective  portal  flow  (portal  vein  thrombosis, 
hepatofugal  flow  in  the  portal  vein,  transjugular 
intrahepatic  portosystemic  shunt),  liver 
decompensation (Child-pugh C), systemic infection, 
significant comorbidity (cardiac and renal failure), 




Controlled  randomized  studies  and  a 
cumulative meta-analysis have demonstrated that in 
patients  with  unresectable HCC,  TACE  achieve 
objective responses lasting 1 to 6 months in 35% 
(range  16%  to  61%)  of  cases  and  determine  a 
significant  benefit,  when  compared  with  best 
supportive  care,  in  terms  of  both  reduced 
progression rate and improved survival
62-64.  These 
results  have  been  fundamental  to  recommend 
TACE  as  the  standard of care  for  patients  in  the 
Intermediate  stage  of  the  BCLC  classification 
(fig.1).  It  must  be  oultlined,  however,  that  about 
90%  of  patients  included  in  the  RCT  taken  into 
account in the Llovet’s metanalysis are in the Child 
Pugh  class  A  and  that  these  trials  were  mostly 
performed  in  patienrs  classified  as  “unresectabe”, 
including also early and advanced cases. Therefore 
the  conclusions  about  widestread  applicability  of 
TACE in intermediate HCC, irrespective of Child 
Pugh A or B class should be critically revised.
TACE  is  associated  with  adverse  events  in 
approximately 10% of treated patients; these events 
include  ischemic  cholecystitis,  nausea,  vomiting, 
bone  marrow  depression,  and  abdominal  pain. 
Moreover, a postembolization syndrome is reported 
in  about  50% of patients treated  with TACE  and 
includes  fever,  abdominal  pain,  and  moderate 
degree  of  intestinal  obstruction.  Treatment-related 
mortality is less than 5% 
65 .
Even if TACE is now the standard treatment for 
unresectable HCC, there is still not a standardized 
protocol for this procedure. Randomized trials are 
actually  ongoing  to  compare  different  types  of 
cytotoxic  drugs,  drug  vehicles,  and  therapeutic 
schemes. 
The potential benefit of TACE as neoadjuvant 
or adjuvant treatment in curative procedure, as well 
as  the  combined  use  of  TACE  with  other 
procedures, are further issues under investigation.  
Palliative  treatment  also  include  radiation 
therapy,  both  internal  and  external.  The  use  of 
external  radiation  is  however  limited  by  the  low 
radiation tolerance of the non-tumoral liver. 
Better  results,  in  terms  of  safety  and  disease 
control rates, are obtained with radioembolization, a 
brachytherapy that consists in delivering radioactive 
implants. 
Microspheres containing radionuclide Yttrium-
90  (Y-90),  a  pure  -emitter,  are  lodged  via  a 
catheter insertion into the hepatic artery that feed 
the  tumors  and  emit  local  radiation  with  limited 
exposure to adjacent healthy tissue
66.
Absolute  contraindications  for  Y-90 
radioembolization  are:  1)  hepatopulmonary  shunt  
that would result in an harmful dose of radiation (> 
30 Gy with a single infusion or > 50 Gy for multiple 
infusions) to the lungs, 2) the inability to prevent 
embolization  of  microspheres  into  the 
gastrointestinal tract, and 3) a history of previous 
external  irradiation  to  the  liver.  Differently  from 
TACE, due to an absent or minimal embolic effect, 
Y-90 radioembolization can be safely performed in 
patients with portal vein occlusion
67. 
Retrospective  analyses  and  small  non-
controlled prospective studies have shown that Y-
90 radioembolization results in high disease control 
rate  with  a  median  survival  for  advanced  HCC 
cases  of  12  months
68-70. At  present,  however,  no 
randomized  trials  comparing  Y-90 
radioembolization  with  locoregional,  systemic 
therapies  or  best  supportive  care,  have  been 
published.  
New Therapies: The management of patients with 
avanced HCC has been characterized for decades by 
limited  therapeutic  options  since  both  hormonal 
compounds  and  conventional  cytotoxic 
chemotherapy  has  failed  to  show  a  substantial 
benefit for patients with HCC
71-73.
A  better  knowledge  of  molecular 
hepatocarcinogenesis  and  the  following 
introduction of targeted agents that specifically act 
on  the  neoplastic  pathways,    have  created  a  new 
therapeutic hope
74.
Very  recently,  positive  results  have  been 
reported  with  the  use  of  sorafenib,  an  oral Medit J Hemat Infect Dis 2009; 1(3); Open Journal System 
multikinase  inhibitor,  which  inhibits  tumor-cell 
proliferation and tumor angiogenesis and increases 
the  rate  of  apoptosis  in  a  wide  range  of  tumor 
models
75.  A  multicentric  international  phase  III 
randomized controlled trial (the SHARP trial) has 
recently  shown  a  3-month  survival  improvement 
with  a  manageable  toxicity in  patients  with 
advanced HCC in Chil-Pugh A cirrhotic stage. The 
median  overall  survival  was  10.7  months  with 
sorafenib and 7.9 months with placebo (hazard ratio 
for  the  sorafenib  group  0.69,  95%  CI  0.55–0.87, 
p=0.005).  Median  time  to  progression  was  5.5
months  with  sorafenib  versus  2.8  months  with 
placebo (p<0.001)
22. 
The most common grade 3 drug-related adverse 
events  observed  in  the  SHARP  study  included 
diarrhoea  and  hand-foot  skin  reaction,  both  of 
which occurred in 8% of all patients treated with 
sorafenib 
A  survival  benefit  of sorafenib  has  been also 
shown in a subsequent randomized phase III study 
conducted in Asia, in patients with advanced HCC. 
In this study, the median overall survival increased 
from 4.1 months in the placebo group to 6.2 months 
in the sorafenib group (hazard ratio in the sorafenib 
group  0.67;  95%  confidence  interval,  0.49–0.93; 
P<0.0155)
76.
As  a  consequence  of  these  results,  the 
indication to Sorafenib treatment is well established 
in Child A patients having advanced HCC with or 
without  extrahepatic  spread  and  vascular 
involvement. 
Thus, any further drug being developed in this 
subgroup of HCC patients will have to be compared 
against the reference standard sorafenib.
Future  Perspectives:  Other  settings  where 
sorafenib is actually under evaluation are: 
1)  intermediate  HCC  (according  to  BCLC 
classification) in combination to TACE: most of 
patients  at  this  stage  were  included  in  the 
SHARP trial and contributed to the significant 
result of this study; 
2)  Child  B  patients  with  advanced  HCC:  most 
patients in Child B have been treated in phase II 
and other studies, as well as in current clinical 
practice  and  the  efficacy  treatment  and  the 
frequency of adverse events seems to be similar 
to that of Child A patients, except perhaps for
bilirubin increase; 
3) Adjuvant setting after surgical or loco-regional 
treatment,  and  in  combiunation  with 
conventional treatments: these perspectives are 
currently  under  investigation  in  clinical  trials, 
as well as combinations with  other molecuar-
targeted  agents  and  second  line  treatments  in 
patients progresing under Sorafenib.
Drugs that specifically target key molecules in 
carcinogenesis have emerged over the last decade. 
The  molecular  targeting  has  become  a  promising 
approach  for  the  effective  treatment  of  various 
cancers,  now  including  also  hepatocellular 
carcinoma. Therefore, several studies evaluating the 
efficacy of  other  molecular  therapies in  HCC are 
currently at different stages of validation in phase I, 
II and III clinical trials. These new therapies include 
molecules  or  monoclonal  antibody  blocking 
different molecular targets which have been shown 
to play a crucial role in HCC proliferation such as 
vascular  endothelial  growth  factor  (VEGF), 
plateled-derived growth factor  (PDGF),  epidermal 
growth  factor  (EGF),  EGF  receptor  (EGFR),  and  
PI3K/Akt/mTOR signaling pathway
74 . 
The demonstration of an altered expression of 
the  target  molecules  should  be  mandatory  in 
defining the inclusion criteria of future studies. This 
could  help  to  define  the  beneficial  effect  in 
restricted but identifiable subgroups of patients and 
to  correctly  allocate  patients  to  the  specific 
treatment.
It is desirable that the positive results obtained 
by  sorafenib  represent  a  first  step  toward  new, 
tumor  biology-based,  therapeutic  chances.  In  this 
regards,  it  is  as  decisive  identify  predictive 
biomarkers to select patients more likely to benefit 
from any specific agent. 
Most probably, major benefits will be obtained 
by combination of agents acting simultaneously on 
distinct molecular targets and bear great hopes for 
the  treament  of  HCC  in  the  next  years.
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